Article
Rheumatology
Christian Ammitzboll, Marianne Kragh Thomsen, Jakob Bogh Andersen, Jens Magnus Berth Jensen, Marie-Louise From Hermansen, Anders Dahl Johannsen, Mads Lamm Larsen, Clara Elbaek Mistegaard, Susan Mikkelsen, Fruzsina Szabados, Signe Risbol Vils, Christian Erikstrup, Ellen-Margrethe Hauge, Anne Troldborg
Summary: This study aimed to investigate the effect of either a booster vaccine or revaccination on the antibody response to COVID-19 mRNA vaccines in rheumatic disease patients treated with rituximab. The study found that most patients had impaired humoral response after the booster dose or revaccination, and approximately one-third of the patients showed seroconversion. Measurable B cells before boosting or revaccination were the strongest predictor of antibody response.
Article
Immunology
Osama Abu-Hammad, Hamza Alduraidi, Shaden Abu-Hammad, Ahmed Alnazzawi, Hamzah Babkair, Abdalla Abu-Hammad, Ibrahim Nourwali, Farah Qasem, Najla Dar-Odeh
Summary: The survey conducted among healthcare professionals who received COVID-19 vaccines in Jordan showed that around 18% and 31% reported no side effects after the first and second doses respectively. Most of the side effects were local, while systemic side effects like fatigue, myalgia, headache, and fever were more common after the first dose, particularly associated with the AstraZeneca vaccine and age <= 45 years. No serious side effects were reported, indicating that the side effects of COVID-19 vaccines in Jordan are similar to what have been known before. Further studies with larger sample sizes and longer follow-up periods are needed to monitor potential serious and long-term side effects.
Article
Immunology
Gokhan Dogukan Akarsu
Summary: The aim of this study was to investigate the health problems experienced by young adults after receiving the COVID-19 vaccine. A total of 590 undergraduate students participated in the study, and the data were collected through interviews and questionnaires. The results showed that one-third of the vaccinated students experienced health problems, including fatigue, cough, and sleep disturbance. Further research in different sample groups is recommended.
Article
Hematology
C. Perry, E. Luttwak, R. Balaban, G. Shefer, M. M. Morales, A. Aharon, Y. Tabib, Y. C. Cohen, N. Benyamini, O. Beyar-Katz, M. Neaman, R. Vitkon, N. Keren-Khadmy, M. Levin, Y. Herishanu, I Avivi
Summary: Patients with B-cell non-Hodgkin lymphoma (B-NHL) undergoing R/Obi treatment have impaired humoral response to the BNT162b2 mRNA COVID-19 vaccine. Longer time since exposure to R/Obi is associated with improved response rates to the COVID-19 vaccine. Multi-variable analysis reveals predictors for a positive serological response.
Article
Immunology
Victoria Furer, Tali Eviatar, Devy Zisman, Hagit Peleg, Yolanda Braun-Moscovici, Alexandra Balbir-Gurman, Daphna Paran, David Levartovsky, Michael Zisapel, Ofir Elalouf, Ilana Kaufman, Adi Broyde, Ari Polachek, Joy Feld, Amir Haddad, Tal Gazitt, Muna Elias, Nizar Higazi, Fadi Kharouf, Sara Pel, Sharon Nevo, Ori Elkayam
Summary: In patients with autoimmune inflammatory rheumatic diseases (AIIRD) treated with rituximab (RTX), the predictors of a positive immunogenic response to the BNT162b2 mRNA vaccine include the number of RTX courses, cumulative RTX dose, IgG level prior to last RTX course, and interval between RTX treatment and vaccination. ANCA-associated vasculitis and inflammatory myositis patients have a low likelihood of a seropositive immunogenic response.
Review
Immunology
Kexin Liu, Jinyu Li, Gaosi Xu
Summary: This study analyzed the optimal interval before SARS-CoV-2 vaccination for patients who had previously received anti-CD20 monoclonal antibodies. The results suggested that the optimal interval after the final dose of anti-CD20 monoclonal antibody was 5.5 months.
Article
Immunology
Sutima Luangdilok, Passakorn Wanchaijiraboon, Nussara Pakvisal, Thiti Susiriwatananont, Nicha Zungsontiporn, Virote Sriuranpong, Panot Sainamthip, Nungruthai Suntronwong, Preeyaporn Vichaiwattana, Nasamon Wanlapakorn, Yong Poovorawan, Nattaya Teeyapun, Suebpong Tanasanvimon
Summary: This study investigated the immune response of solid cancer patients who previously received a heterologous CoronaVac/ChAdOx1 vaccine to a third mRNA COVID-19 vaccine. Results showed a significant increase in antibody levels after the third dose, with no statistical difference between different vaccine regimens. Endocrine therapy/biologics had a better antibody response compared to chemotherapy. Additionally, there was no significant difference in the immune response after the third dose between cancer patients and healthy individuals who received the same heterologous CoronaVac/ChAdOx1 vaccination.
Article
Immunology
Martina Fabris, Ginevra De Marchi, Rossana Domenis, Federica Caponnetto, Silvia Guella, Chiara Dal Secco, Nicola Cabas, Salvatore De Vita, Antonio Paolo Beltrami, Francesco Curcio, Luca Quartuccio
Summary: This study evaluated the immune response to SARS-CoV-2 mRNA vaccination in patients with complex or rare systemic autoimmune diseases who were previously treated with or under continuous treatment with B-cell-targeted therapies. The results showed that even in the absence of circulating B cells, virus-specific cellular immunity can be induced, indicating that B-cell-targeted therapies do not preclude SARS-CoV-2 vaccination.
JOURNAL OF AUTOIMMUNITY
(2022)
Article
Multidisciplinary Sciences
Yi-Qing Zheng, He-Jun Li, Ling Chen, Shun-Ping Lin
Summary: This study investigated the immunogenicity of the inactivated COVID-19 vaccine in patients with autoimmune inflammatory rheumatic diseases (AIIRD). The study found that AIIRD patients had a similar immune response to the vaccine compared to the general population, but treatment with rituximab may impair the vaccine's immunogenicity. Low doses of glucocorticoids and hydroxychloroquine had negligible effects on the vaccine's immunogenicity.
SCIENTIFIC REPORTS
(2022)
Article
Immunology
Stefania Bruno, Lorenza Nachira, Paola Arcaro, Fabio Pattavina, Enrica Campo, Chiara Cadeddu, Brigida Carducci, Antonio Lanzone, Gianfranco Damiani, Patrizia Laurenti
Summary: This study aimed to investigate pregnant women's appreciation of COVID-19 vaccination and factors impacting vaccine hesitancy. A questionnaire was administered to pregnant women who had received their immunization at a teaching hospital in Rome. The results showed a high appreciation of the vaccination services, low to medium levels of pre-vaccinal doubt, high knowledge of COVID-19 vaccine, and physicians playing a decisive role in vaccination choice.
Article
Immunology
Azam Safary, Kamal Esalatmanesh, Amir Taher Eftekharsadat, Mohammad -Reza Jafari Nakjavani, Alireza Khabbazi
Summary: Vaccination against COVID-19 is important for achieving herd immunity and controlling the pandemic. However, a small number of people may develop autoimmune rheumatic diseases (ARDs) as a rare adverse reaction to the vaccines. This study identifies individuals who developed de-novo ARDs after COVID-19 vaccination, with a higher prevalence among those who received the AstraZeneca vaccine. Prompt diagnosis and treatment can prevent irreversible organ damage.
INTERNATIONAL IMMUNOPHARMACOLOGY
(2022)
Article
Clinical Neurology
Guillaume Dorcet, Hugo Migne, Damien Biotti, Chloe Bost, Fleur Lerebours, Jonathan Ciron, Emmanuel Treiner
Summary: EBR is common in rituximab-treated MS patients and is not associated with clinical disease activity. EBR in the peripheral blood may reflect regulatory immunological phenomena in subgroup of patients.
JOURNAL OF NEUROLOGY
(2022)
Review
Rheumatology
Mehmet Soy, Gokhan Keser, Pamir Atagunduz, Melek Yalcin Mutlu, Alper Gunduz, Gizem Koybasi, Cemal Bes
Summary: The article discusses the importance of COVID-19 vaccination in AIIRD patients and provides precautions to be taken before vaccination, including vaccination when disease activity is under control and before the use of biological DMARDs.
CLINICAL RHEUMATOLOGY
(2021)
Article
Immunology
Matt Motta
Summary: The study found that willingness to receive a second COVID-19 booster shot is low among Americans, with reasons including concerns about missing work and skepticism towards the necessity of additional boosters.
Review
Rheumatology
Jack Arnold, Kevin Winthrop, Paul Emery
Summary: This article discusses the impact of immunosuppressive therapy on COVID-19 vaccination, proposing a suggestion to temporarily suspend treatment to improve vaccine effectiveness, and urging decisions on withholding immunosuppressive therapy to be made in advance without sufficient data support.
Review
Clinical Neurology
Mia Minen, Sarah Jinich, Gladys Vallespir Ellett
Article
Rheumatology
Robert Spiera, Laura Hummers, Lorinda Chung, Tracy M. Frech, Robyn Domsic, Vivien Hsu, Daniel E. Furst, Jessica Gordon, Maureen Mayes, Robert Simms, Robert Lafyatis, Viktor Martyanov, Tammara Wood, Michael L. Whitfield, Scott Constantine, Elizabeth Lee, Nancy Dgetluck, Barbara White
ARTHRITIS & RHEUMATOLOGY
(2020)
Letter
Rheumatology
Robert Spiera, Lorinda Chung, Tracy Frech, Robyn Domsic, Vivien Hsu, Daniel E. Furst, Robert Simms, Maureen Mayes, Viktor Martyanov, Michael L. Whitfield, Nancy Dgetluck, Quinn Dinh, Barbara White
ARTHRITIS & RHEUMATOLOGY
(2021)
Letter
Rheumatology
Robert Spiera, Sarah Jinich, Deanna Jannat-Khah
ANNALS OF THE RHEUMATIC DISEASES
(2021)
Article
Rheumatology
Sebastian E. Sattui, Deanna Jannat-Khah, Lindsay Lally, Sarah B. Lieber, Lisa A. Mandl, Robert F. Spiera
Summary: This study found a higher prevalence of frailty among patients with PMR, which was associated with worse health-related quality of life, increased pain behavior, and interference.
Article
Rheumatology
Dinesh Khanna, Paul Caldron, Richard W. Martin, Suzanne Kafaja, Robert Spiera, Shadi Shahouri, Ankoor Shah, Vivien Hsu, John Ervin, Robert Simms, Robyn T. Domsic, Virginia Steen, Laura K. Hummers, Chris Derk, Maureen Mayes, Soumya Chatterjee, John Varga, Steven Kesten, John K. Fraser, Daniel E. Furst
Summary: This study evaluated the capacity of autologous adipose-derived regenerative cells (ADRCs) to improve hand function in systemic sclerosis (SSc) patients. The results showed that ADRC treatment resulted in a numerically higher improvement in hand function compared to placebo, although it did not achieve statistical significance. For patients with diffuse cutaneous SSc (dcSSc), ADRC treatment showed significant improvement in hand function and health assessment index compared to placebo.
ARTHRITIS & RHEUMATOLOGY
(2022)
Article
Rheumatology
Gabriele Gamerith, Finn Mildner, Peter A. Merkel, Kristina Harris, Laura Cooney, Noha Lim, Robert Spiera, Philip Seo, Carol A. Langford, Gary S. Hoffman, E. William St Clair, Fernando C. Fervenza, Paul Monach, Steven R. Ytterberg, Duvuru Geetha, Arno Amann, Dominik Wolf, Ulrich Specks, John H. Stone, Andreas Kronbichler
Summary: This study investigated the predictive role of soluble immune checkpoints (sICPs) in patients with antineutrophil cytoplasm antibody (ANCA)-associated vasculitis (AAV). The study found that in patients treated with rituximab, low concentrations of sLag-3 and high concentrations of sCD27 were associated with treatment failure, while high concentrations of sTim-3, sCD27, and sBTLA at baseline predicted relapse in patients reaching remission. These results suggest that sICPs could play a role in personalized treatment approaches for AAV.
ANNALS OF THE RHEUMATIC DISEASES
(2023)
Article
Immunology
Vidyanath Chaudhary, Marie Dominique Ah Kioon, Sung-Min Hwang, Bikash Mishra, Kimberly Lakin, Kyriakos A. Kirou, Jeffrey Zhang-Sun, R. Luke Wiseman, Robert F. Spiera, Mary K. Crow, Jessica K. Gordon, Juan R. Cubillos-Ruiz, Franck J. Barrat
Summary: This article reports that pDCs from autoimmune patients have defects in the regulation of metabolic pathways and that blocking the TCA cycle abrogates chronic IFN-I responses. Modulating the IRE1 alpha-XBP1-PHGDH axis may represent a hitherto unexplored strategy for alleviating chronic pDC activation in autoimmune disorders.
JOURNAL OF EXPERIMENTAL MEDICINE
(2022)
Article
Rheumatology
Kaitlin Schultz, Deanna Jannat-Khah, Robert Spiera
Summary: Factors associated with serologic response to the COVID-19 booster vaccine in autoimmune rheumatic disease patients treated with RTX include B cell reconstitution and time since last RTX exposure.
JOURNAL OF RHEUMATOLOGY
(2023)
Article
Rheumatology
Robert Spiera, Masataka Kuwana, Dinesh Khanna, Laura M. Hummers, Tracy Frech, Wendy Stevens, Marco Matucci-Cerinic, Suzanne Kafaja, Oliver Distler, Jae-Bum Jun, Yair Levy, Piotr Leszcyznski, Jessica Gordon, Virginia Steen, Eun Bong Lee, Tomasz Jankowski, Irena Litinsky, Lorina Chung, Vivien Hsu, Maureen Mayes, Nora W. Sandorfi, Robert Simms, Stephanie Finzel, Jeska de Vries-Bouwstra, Scott Constantine, Nancy Dgetluck, Quinn J. Dinh, Bradley E. Bloom, Daniel Furst, Barbara P. White, Christopher Denton
Summary: The efficacy and safety of lenabasum in dcSSc patients were investigated. The study failed to demonstrate a benefit of lenabasum in dcSSc, but showed better outcomes in patients treated with background IST, particularly mycophenolate mofetil.
ARTHRITIS & RHEUMATOLOGY
(2023)
Article
Rheumatology
Peter A. Merkel, John Niles, Richard Jimenez, Robert F. Spiera, Brad H. Rovin, Andrew Bomback, Christian Pagnoux, Antonia Potarca, Thomas J. Schall, Pirow Bekker
ACR OPEN RHEUMATOLOGY
(2020)
Article
Health Care Sciences & Services
Mia T. Minen, Samrachana Adhikari, Elizabeth K. Seng, Thomas Berk, Sarah Jinich, Scott W. Powers, Richard B. Lipton
NPJ DIGITAL MEDICINE
(2019)